Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Silliker Announces Proprietary Testing Method Licensing Agreement with Kraft Foods
Silliker has announced a licensing agreement with Kraft Foods for a patent pending in vitro method for predicting the Glycemic Index (GI) of foods.
- Silliker Announces Proprietary Testing Method Licensing Agreement with Kraft Foods
Silliker has announced a licensing agreement with Kraft Foods for a patent pending in vitro method for predicting the Glycemic Index (GI) of foods.
- Silliker Announces Proprietary Testing Method Licensing Agreement with Kraft Foods
Silliker has announced a licensing agreement with Kraft Foods for a patent pending in vitro method for predicting the Glycemic Index (GI) of foods.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- Nu Skin Enterprises and Toyo Bio-Pharma Enter Agreement for Joint Product Research and Development
Nu Skin Enterprises, Inc. (NUS) has announced that it has has signed a memorandum of understanding for a joint research and development relationship with Toyo Bio-Pharma, Inc. (a subsidiary of Toyo Shinyaku, Japan), a natural products manufacturer with facilities in the United States and Japan. To facilitate this relationship, the companies established a new joint venture, NU Toyo Research, Inc., in the United States.
- SunOpta Announces First Quarter 2008 Results
SunOpta Inc. (STKL) (CA:SOY) has announced FY08 Q1 results, reporting revenues of $230,444,000 as compared to $183,500,000 in the first quarter of 2007, with earnings of $1,486,000 or $0.02 per diluted common share as compared to 2007 first quarter earnings of $1,055,000 or $0.02 per diluted common share.
- SunOpta Announces First Quarter 2008 Results
SunOpta Inc. (STKL) (CA:SOY) has announced FY08 Q1 results, reporting revenues of $230,444,000 as compared to $183,500,000 in the first quarter of 2007, with earnings of $1,486,000 or $0.02 per diluted common share as compared to 2007 first quarter earnings of $1,055,000 or $0.02 per diluted common share.
- SunOpta Announces First Quarter 2008 Results
SunOpta Inc. (STKL) (CA:SOY) has announced FY08 Q1 results, reporting revenues of $230,444,000 as compared to $183,500,000 in the first quarter of 2007, with earnings of $1,486,000 or $0.02 per diluted common share as compared to 2007 first quarter earnings of $1,055,000 or $0.02 per diluted common share.
- Greg Horn Named Solbar North American Business Director
Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins.
- Greg Horn Named Solbar North American Business Director
Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins.
- Greg Horn Named Solbar North American Business Director
Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins.
- Greg Horn Named Solbar North American Business Director
Solbar Industries Ltd. has announced the appointment of Greg Horn to direct the company's business, marketing and sales activities in North America (U.S. and Canada), beginning August 1st, 2008, to be responsible for implementing Solbar's business marketing plan focused on specialty soy proteins including isolates, functional and textured soy concentrates and Solbar's Bontex steam-textured soy proteins.
- Reliv International Reports Second-Quarter Results; Restructures European Operations
Reliv International, Inc. (RELV) has announced FY08 Q12 results, reporting net sales of $24.0 million, compared to net sales of $26.3 million in the second quarter last year, with net income of $569,000 or $0.04 per diluted share, compared to net income of $823,000 or $0.05 per diluted share in the second quarter of 2007.
- Reliv International Reports Second-Quarter Results; Restructures European Operations
Reliv International, Inc. (RELV) has announced FY08 Q12 results, reporting net sales of $24.0 million, compared to net sales of $26.3 million in the second quarter last year, with net income of $569,000 or $0.04 per diluted share, compared to net income of $823,000 or $0.05 per diluted share in the second quarter of 2007.
- Nu Skin Enterprises Reports Second-Quarter 2008 Results
Nu Skin Enterprises, Inc. (NUS) has announced FY08 Q2 results, reporting revenue of $321.7 million, a 12 percent improvement over the prior-year period, with earnings per share of $0.32 compared to $0.21 for the same quarter of 2007.
- Nu Skin Enterprises Reports Second-Quarter 2008 Results
Nu Skin Enterprises, Inc. (NUS) has announced FY08 Q2 results, reporting revenue of $321.7 million, a 12 percent improvement over the prior-year period, with earnings per share of $0.32 compared to $0.21 for the same quarter of 2007.
- Nutraceutical Reports Q3 Results
Nutraceutical International Corporation (NUTR) has announced FY08 Q3 results, reporting net sales of $40.5 million compared to $38.7 million for the same quarter prior year, with net income of $2.9 million, or $0.26 diluted earnings per share, compared to net income of $2.9 million, or $0.25 diluted earnings per share, for the same quarter of fiscal 2007.
- Nutraceutical Reports Q3 Results
Nutraceutical International Corporation (NUTR) has announced FY08 Q3 results, reporting net sales of $40.5 million compared to $38.7 million for the same quarter prior year, with net income of $2.9 million, or $0.26 diluted earnings per share, compared to net income of $2.9 million, or $0.25 diluted earnings per share, for the same quarter of fiscal 2007.
- Balchem Corporation Announces 2nd Quarter 2008 Results
Balchem Corporation (BCPC) has announced FY08 Q2 results, reporting net sales of $62.9 million compared to $44.4 million prior year, with net earnings of $4.7 million, an increase of $0.7 million, or 16.2% as compared with the same period last year. Sales of the Food, Pharma and Nutrition segment were $9.5 million, an increase of 19.6% from the prior year comparable quarter.
- Balchem Corporation Announces 2nd Quarter 2008 Results
Balchem Corporation (BCPC) has announced FY08 Q2 results, reporting net sales of $62.9 million compared to $44.4 million prior year, with net earnings of $4.7 million, an increase of $0.7 million, or 16.2% as compared with the same period last year. Sales of the Food, Pharma and Nutrition segment were $9.5 million, an increase of 19.6% from the prior year comparable quarter.
- PacificHealth Laboratories Reports Second Quarter 2008 Results
PacificHealth Laboratories, Inc. (PHLI) has announced Fy08 Q2 results, reporting revenues of $2,370,429 compared to $2,069,889 for the same period in 2007, with a net loss of ($146,608), or ($0.01) per share compared to a net loss of ($127,276), or ($0.01) per share, for the same period in 2007.
- PacificHealth Laboratories Reports Second Quarter 2008 Results
PacificHealth Laboratories, Inc. (PHLI) has announced Fy08 Q2 results, reporting revenues of $2,370,429 compared to $2,069,889 for the same period in 2007, with a net loss of ($146,608), or ($0.01) per share compared to a net loss of ($127,276), or ($0.01) per share, for the same period in 2007.
- Fenchem Maintains Competitive Vitamin E price
The price of Fenchem’s TOCOVET® natural source vitamin E in North America is being maintained within the marketplace, due to large stocks and expanding production.
- Fenchem Maintains Competitive Vitamin E price
The price of Fenchem’s TOCOVET® natural source vitamin E in North America is being maintained within the marketplace, due to large stocks and expanding production.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement in which Croda will have an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm’s proprietary microbial library for use in topical cosmetic applications in skin and hair care.
- DNP Notches 8% Second Quarter Increase
DNP International has reported an eight percent second quarter increase compared to last year during the same time.
- DNP Notches 8% Second Quarter Increase
DNP International has reported an eight percent second quarter increase compared to last year during the same time.
- Natural Alternatives International, Inc. Announces Sale of 'As We Change(R)' Assets and Provides Fourth Quarter Revenue Update
Natural Alternatives International, Inc. (NAII) has announced that it has sold the "As We Change(R)" catalog and internet business of Real Health Laboratories, Inc., its wholly owned subsidiary, for $2.0 million subject to certain adjustments.
- Natural Alternatives International, Inc. Announces Sale of 'As We Change(R)' Assets and Provides Fourth Quarter Revenue Update
Natural Alternatives International, Inc. (NAII) has announced that it has sold the "As We Change(R)" catalog and internet business of Real Health Laboratories, Inc., its wholly owned subsidiary, for $2.0 million subject to certain adjustments.
- Herbalife announces record Q2 results
Herbalife Ltd. (HLF) has announced FY08 Q2 results, reporting net sales of $639.7 million, an increase of 20.7 percent compared to the same period of 2007, with net income of $67.1 million, or $1.01 per diluted share, compared to $48.1 million, or $0.65 per diluted share in the second quarter of 2007.
- Herbalife announces record Q2 results
Herbalife Ltd. (HLF) has announced FY08 Q2 results, reporting net sales of $639.7 million, an increase of 20.7 percent compared to the same period of 2007, with net income of $67.1 million, or $1.01 per diluted share, compared to $48.1 million, or $0.65 per diluted share in the second quarter of 2007.
- Jamba, Inc. Announces Changes to Its Senior Management Team
Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen.
- Jamba, Inc. Announces Changes to Its Senior Management Team
Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen.
- Jamba, Inc. Announces Changes to Its Senior Management Team
Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen.
- Jamba, Inc. Announces Changes to Its Senior Management Team
Jamba, Inc. (JMBA) has announced that Steven R. Berrard, the Company's Chairman of the Board, has assumed the role of interim Chief Executive Officer and President of the Company, replacing Paul E. Clayton, and Karen Luey, Vice President, Controller, and Principal Accounting Officer of the Company, has assumed the role of interim Chief Financial Officer of the Company, replacing Donald D. Breen.
- General Nutrition Centers, Inc. Reports Second Quarter 2008 Financial Results
General Nutrition Centers, Inc. has announced FY08Q2 results, with reported revenues of $422.7 million, an 8.5% increase over the same quarter in 2007. This increase was the result of increased revenues in each of the Company's business segments: Retail by 6.3%; Franchise by 8.6%; and Manufacturing/Wholesale by 28.0%. Same store sales improved 4.5% in domestic company-owned stores (including internet sales), and 5.2% in Canadian stores
- General Nutrition Centers, Inc. Reports Second Quarter 2008 Financial Results
General Nutrition Centers, Inc. has announced FY08Q2 results, with reported revenues of $422.7 million, an 8.5% increase over the same quarter in 2007. This increase was the result of increased revenues in each of the Company's business segments: Retail by 6.3%; Franchise by 8.6%; and Manufacturing/Wholesale by 28.0%. Same store sales improved 4.5% in domestic company-owned stores (including internet sales), and 5.2% in Canadian stores
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff
Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced.
- Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff
Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced.
- Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff
Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced.
- Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff
Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced.
- Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff
Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced.
- Sprunk-Jansen Launches Products Based On Greek-Arabic System, Opens US Office, Announces Staff
Sprunk-Jansen have announced the opening of their U.S. operation, along with a new sales team, Chief Operating Officer, President of U.S. operations and others involved in the company. Newly available products are also introduced.
- Senomyx Announces Second Quarter 2008 Financial Results
Senomyx has announced FY08Q2 results, reporting Q2 revenues of $9.6 million for the six months ended June 30, 2008, compared to $6.8 million for the six months ended June 30, 2007.
- Senomyx Announces Second Quarter 2008 Financial Results
Senomyx has announced FY08Q2 results, reporting Q2 revenues of $9.6 million for the six months ended June 30, 2008, compared to $6.8 million for the six months ended June 30, 2007.
- ChromaDex Completes $4.67 Million Capital Raise in Private Placement Transaction
ChromaDex Corporation has announced that on July 29, 2008, it completed its last round of sales under a private placement. The private placement, which was authorized for up to $6 million and has been on-going since March, yielded gross proceeds of approximately $4.67 million.
- ChromaDex Completes $4.67 Million Capital Raise in Private Placement Transaction
ChromaDex Corporation has announced that on July 29, 2008, it completed its last round of sales under a private placement. The private placement, which was authorized for up to $6 million and has been on-going since March, yielded gross proceeds of approximately $4.67 million.
- ChromaDex Completes $4.67 Million Capital Raise in Private Placement Transaction
ChromaDex Corporation has announced that on July 29, 2008, it completed its last round of sales under a private placement. The private placement, which was authorized for up to $6 million and has been on-going since March, yielded gross proceeds of approximately $4.67 million.
- Omega Protein Reports Second Quarter Results
Omega Protein Corporation has announced FY08Q2 results, reporting a Q2 income of $6.7 million ($0.37 per share) with a net income of $2.5 million ($0.15 per share) for the second quater of the previous year.
- Omega Protein Reports Second Quarter Results
Omega Protein Corporation has announced FY08Q2 results, reporting a Q2 income of $6.7 million ($0.37 per share) with a net income of $2.5 million ($0.15 per share) for the second quater of the previous year.
- Omega Protein Reports Second Quarter Results
Omega Protein Corporation has announced FY08Q2 results, reporting a Q2 income of $6.7 million ($0.37 per share) with a net income of $2.5 million ($0.15 per share) for the second quater of the previous year.
- NutraCea Announces Second Quarter 2008 Financial Results
NutraCea (NTRZ) has announced FY08 Q2 results, reporting net revenues of $10.3 million for the second quarter of 2008, compared to net revenues of $13.0 million for the second quarter of 2007, with a one-time license fee of $5.0 million (non-recurring) without which net revenues for the second quarter 2007 would have been $8,000,000. Net loss for the second quarter of 2008 was $6.1 million, or $(0.04) per share, compared to net income of $2.0 million or $0.01 per share for the same period last year.
- NutraCea Announces Second Quarter 2008 Financial Results
NutraCea (NTRZ) has announced FY08 Q2 results, reporting net revenues of $10.3 million for the second quarter of 2008, compared to net revenues of $13.0 million for the second quarter of 2007, with a one-time license fee of $5.0 million (non-recurring) without which net revenues for the second quarter 2007 would have been $8,000,000. Net loss for the second quarter of 2008 was $6.1 million, or $(0.04) per share, compared to net income of $2.0 million or $0.01 per share for the same period last year.
- KI NutriCare to Acquire Allergy Research Group for $1.33 Per Share in an All Cash Tender Offer Valued at Approximately $19,500,000
KI NutriCare, Inc. and Allergy Research Group, Inc. (ALRG) have announced that KI NutriCare, a wholly-owned subsidiary of Kikkoman Corporation (TSE:2801), Longhorn Acquisition Corp., a wholly-owned subsidiary of KI NutriCare formed to effect the transaction, and Allergy Research Group have entered into a definitive agreement pursuant to which Allergy Research Group will be acquired for approximately $19,500,000 through an all cash tender offer of $1.33 per share by Longhorn Acquisition Corp.
- KI NutriCare to Acquire Allergy Research Group for $1.33 Per Share in an All Cash Tender Offer Valued at Approximately $19,500,000
KI NutriCare, Inc. and Allergy Research Group, Inc. (ALRG) have announced that KI NutriCare, a wholly-owned subsidiary of Kikkoman Corporation (TSE:2801), Longhorn Acquisition Corp., a wholly-owned subsidiary of KI NutriCare formed to effect the transaction, and Allergy Research Group have entered into a definitive agreement pursuant to which Allergy Research Group will be acquired for approximately $19,500,000 through an all cash tender offer of $1.33 per share by Longhorn Acquisition Corp.
- Synutra Achieved 88.7% Net Sales Growth for the First Quarter Ended June 30, 2008
Company reports Q1 net sales in the first quarter ended June 30, 2008 increased by 88.7% to $127.4 million, compared to $67.5 million for the same quarter in 2007. First quarter net income increased by 193.0% to $15.6 million, compared to net income of $5.3 million in the same period in 2007. Synutra earned $0.29 per share (basic) in the first quarter of fiscal 2008, up 163.6% from $0.11 earned in the prior year period.
- Synutra Achieved 88.7% Net Sales Growth for the First Quarter Ended June 30, 2008
Company reports Q1 net sales in the first quarter ended June 30, 2008 increased by 88.7% to $127.4 million, compared to $67.5 million for the same quarter in 2007. First quarter net income increased by 193.0% to $15.6 million, compared to net income of $5.3 million in the same period in 2007. Synutra earned $0.29 per share (basic) in the first quarter of fiscal 2008, up 163.6% from $0.11 earned in the prior year period.
- Schiff Nutrition International, Inc. Announces Fiscal 2008 Fourth Quarter and Year-End Results
Schiff Nutrition International, Inc., has announced FY08 Q4 results reporting net sales were $50.4 million for the three months ended May 31, 2008, compared to $43.2 million for the same period in fiscal 2007. For the fiscal 2008 fourth quarter, Schiff Nutrition reported net income of $2.8 million, or $0.10 per diluted share, compared to net income of $3.7 million, or $0.13 per diluted share, for the same period a year ago. Schiff Nutrition's net sales were $176.9 million for the year ended May 31, 2008, compared to $172.7 million for fiscal 2007. For fiscal 2008, Schiff Nutrition reported net income of $11.3 million, or $0.40 per diluted share, compared to net income of $12.4 million, or $0.45 per diluted share, for fiscal 2007.
- Schiff Nutrition International, Inc. Announces Fiscal 2008 Fourth Quarter and Year-End Results
Schiff Nutrition International, Inc., has announced FY08 Q4 results reporting net sales were $50.4 million for the three months ended May 31, 2008, compared to $43.2 million for the same period in fiscal 2007. For the fiscal 2008 fourth quarter, Schiff Nutrition reported net income of $2.8 million, or $0.10 per diluted share, compared to net income of $3.7 million, or $0.13 per diluted share, for the same period a year ago. Schiff Nutrition's net sales were $176.9 million for the year ended May 31, 2008, compared to $172.7 million for fiscal 2007. For fiscal 2008, Schiff Nutrition reported net income of $11.3 million, or $0.40 per diluted share, compared to net income of $12.4 million, or $0.45 per diluted share, for fiscal 2007.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- New Company for “Change-The-World” Entrepreneurs™ Launches
|
Whole Foods Market, Inc. today reported results for the 12-week third quarter ended July 6, 2008. Sales increased 21.6% to approximately $1.8 billion. Comparable store sales increased 2.6%, and identical store sales, excluding two relocated stores and two major expansions, increased 1.9%. Net income was approximately $33.9 million, and diluted earnings per share were $0.24. The Company estimates the negative impact on net income from Wild Oats was approximately $4.9 million, or $0.03 per diluted share, in the quarter. Earnings before interest, taxes, depreciation and amortization ("EBITDA") were approximately $122 million, and earnings before interest, taxes, depreciation and other non-cash expenses ("EBITANCE") were approximately $135 million. Approximately $71 million relating to depreciation and amortization, share-based payments, LIFO and deferred rent was expensed for accounting purposes but was non-cash.
"Our business model has been highly successful, and we remain very bullish on our growth prospects as the market for natural and organic products continues to grow and as our company continues to evolve; however, the challenging economic environment appears to be negatively impacting our sales," said John Mackey, chairman, chief executive officer, and co-founder of Whole Foods Market. "This, combined with our commitment to maintaining financial flexibility and investing prudently in our long-term growth, has led us to take a more conservative approach to our growth and business strategy over the short term." The key components of this strategy are as follows:
-- The Company is reducing the number of stores expected to open in fiscal year 2009 to approximately 15 and has cut all discretionary capital expenditure budgets not related to new stores by 50%. The Company is committed to actively managing its capital expenditures and does not intend to access the capital markets for additional funding in the foreseeable future; -- the Company has already implemented certain cost containment measures for the remainder of this fiscal year and expects G&A expenses of approximately 3.2% of sales in fiscal year 2009; and -- the Company is suspending its quarterly cash dividend for the foreseeable future.
"We have not undertaken any of these difficult decisions lightly," said Mr. Mackey. "We are committed to improving our financial results and believe these proactive steps are necessary to manage through the current challenging environment, enabling us to emerge stronger and better positioned to realize our growth potential and fulfill our long-term mission and core values."
During the quarter, the Company produced approximately $110 million in cash flow from operations and received approximately $2 million in proceeds from the exercise of stock options. Capital expenditures were approximately $125 million of which approximately $110 million related to new stores and approximately $8 million related to Wild Oats stores. In addition, the Company paid approximately $28 million in cash dividends to shareholders. At the end of the quarter, the Company had total debt of approximately $840 million, including $106 million drawn on its credit line. The Company increased its credit line to $350 million during the third quarter and currently has $123 million available on the facility.
For the 40-week period ended July 6, 2008, sales increased 27.2% to $6.2 billion. Comparable store sales increased 6.4%, and identical store sales, excluding five relocated stores and three major expansions, increased 4.9%. Net income was approximately $113.0 million, and diluted earnings per share were $0.81. The Company estimates the negative impact on net income from Wild Oats was approximately $25.3 million, or $0.18 per diluted share. Earnings before interest, taxes, depreciation and amortization ("EBITDA") were approximately $403 million year to date, and earnings before interest, taxes, depreciation and other non-cash expenses ("EBITANCE") were approximately $446 million. Year to date, approximately $233 million relating to share-based payments, depreciation and amortization, LIFO and deferred rent was expensed for accounting purposes but was non-cash.
Year to date, the Company has produced approximately $267 million in cash flow from operations and has received approximately $18 million in proceeds from the exercise of stock options. Capital expenditures were approximately $392 million of which $283 million related to new stores and approximately $25 million related to Wild Oats stores. In addition, the Company has paid approximately $81 million in cash dividends to shareholders.
Additionally, the Board of Directors has increased the Company's stock repurchase authorization by $100 million, bringing the total current authorization to $200 million.
The following information excludes the estimated quantifiable impact of acquired operations. The following table shows the Company's growth in sales, comparable store sales, and ending square footage year to date compared to its historical five-year ranges and averages. The table also shows the Company's year-to- date results for certain line items as a percentage of sales compared to its historical five-year ranges and averages, and the percentage of sales from identical as well as new and relocated stores year to date compared to its historical five-year ranges and averages. The Company believes this is relevant information as new and relocated stores tend to have lower gross profit and higher direct store expenses as a percentage of sales, resulting in a lower store contribution than identical stores. Where applicable, historical percentages have been adjusted to exclude Hurricane Katrina charges and credits, as well as share-based payments expense incurred in fiscal year 2005 related to the Company's September 2005 accelerated vesting of stock options.
For the third quarter, sales increased 10.5% to approximately $1.7 billion. Gross profit decreased 82 basis points from the prior year to 34.7% of sales. The LIFO charge was approximately $2.7 million versus $2.1 million in the prior year. Direct store expenses increased 29 basis points to 26.4% of sales. Store contribution decreased 111 basis points to 8.4% of sales from 9.5% of sales last year.
For stores in the identical store base, gross profit decreased 48 basis points to 35.2% of sales against a difficult year-ago comparison of 35.6%. Direct store expenses improved 26 basis points to 25.8% of sales due primarily to leverage in wages and share-based payments expense, which was partially offset by an increase in health care costs as a percentage of sales. Store contribution decreased 22 basis points to 9.4% of sales. G&A expenses increased 28 basis points to 3.5% of sales largely due to the costs of integrating and supporting the Wild Oats stores, as well as front- loaded G&A expenditures to support expected future growth.
Excluding the estimated quantifiable impact of the Wild Oats acquisition as discussed in the following section, adjusted net income was approximately $38.8 million, and adjusted diluted earnings per share were $0.28.
Estimated Impact of Wild Oats on the Quarter and Fiscal Year Sales at the Wild Oats stores in operation during the third quarter were $168.3 million, or 9.1% of total sales. The Company closed six Wild Oats stores during the quarter, two of which were in connection with the opening of new Whole Foods Market stores, and re-opened one Wild Oats store that had been closed for a major renovation. Sales for the 57 continuing stores were $164.2 million in the third quarter, and comparable store sales growth was 5.4%.
"We continue to be very pleased with the sales trends we are seeing at the Wild Oats stores. In the third quarter, comparable store sales increased 5.4%, and we have seen a 7.2% increase for the first four weeks of the fourth quarter," said Mr. Mackey. "In the 38 stores we have re-branded thus far, we have seen sales growth double from 6% before re-branding to 12% after."
As highlighted in the following table, the Company estimates the negative impact on net income from Wild Oats in the quarter was approximately $4.9 million, or $0.03 per diluted share. This estimate excludes unquantifiable synergies and costs in the core business.
On July 29, 2008, the United States Court of Appeals for the District of Columbia, in a split decision, reversed the denial of the Federal Trade Commission's (FTC) request for an injunction regarding the Company's acquisition of Wild Oats and remanded the case to the U.S. District Court for further evidentiary proceedings. Whole Foods Market is disappointed with this decision, as customers and Team Members have already received many benefits from this merger. The Company is evaluating its legal options, which include seeking review by the entire Court of Appeals. While the Company disagrees with the reversal of the lower court decision denying the FTC's request for a preliminary injunction, the decision acknowledges that neither the Court nor the FTC has found the merger to be unlawful. United Kingdom Operations
The Company operates six stores in the U.K., five of which were acquired and one store in Kensington which the Company opened last June. Over the last four quarters, these six stores, including the regional office G&A infrastructure, had pre-tax operating losses of approximately $18.4 million, or $0.09 per diluted share. The Company is focused on improving future results in the U.K. and expects to reduce its pre-tax operating losses to $13 million in fiscal year 2009, $7 million in fiscal year 2010, and to approach break even in fiscal year 2011. "We initially lost money when we entered into Canada as well; however, our stores there continue to grow and improve each year and are now very profitable, earning $14.6 million before taxes, or $0.07 per diluted share, over the last four quarters," said Mr. Mackey. "We believe the long-term growth potential in the U.K. is much greater than in Canada. We are carefully evaluating all aspects of our operations in the U.K., with the intent to improve our results over the short term and deliver strong returns over the long term." Growth and Development
In the third quarter, the Company opened four new stores in Hillsboro, OR; Orlando, FL; St. Louis, MO; and Reno, NV and re-opened a remodeled Wild Oats store in Medford, MA. The Company also closed six Wild Oats stores, two in connection with the opening of new Whole Foods Market stores. The Company ended the quarter with 271 stores totaling 9.6 million square feet. Subsequent to the close of the quarter, the Company opened two new stores in New York City, NY and Naperville, IL and closed one store in Rochester Hills, MI which will relocate to another Rochester Hills location tomorrow.
The Company recently signed two new store leases averaging 46,000 square feet in size in New York City, NY and Fairview, TX (a Dallas suburb). The Company also terminated five leases in development totaling approximately 244,000 square feet for stores scheduled to open in fiscal year 2009 and beyond. In addition, since announcing in the third quarter of 2007 the Company's intent to decrease the size of several leases in development, the Company has downsized eight leases by an average of 9,000 square feet each.
The following table provides additional information about the Company's store openings last fiscal year and thus far in fiscal year 2008, leases currently tendered but not opened, and total development pipeline for stores scheduled to open through fiscal year 2012. For accounting purposes, a store is considered tendered on the date the Company takes possession of the space for construction and other purposes, which is typically when the shell of the store is complete or nearing completion. The average tender period, or length of time between tender date and opening date, will vary depending on several factors, one of which is the number of acquired leases, ground leases and owned properties in development, all of which generally have longer tender periods than standard operating leases.
Growth Goals for Fiscal Year 2008 The Company notes that fiscal year 2008 is a 52-week year comparing against 53 weeks last year, with the extra week last year falling in the fourth quarter, making it a thirteen-week quarter.
For the first four weeks of the fourth quarter ended August 3, 2008, comparable store sales increased 1.5%, and identical store sales grew 0.9%. Comparable sales at the 57 continuing Wild Oats stores increased 7.2% over the same period. If the Company's comparable store sales growth for the fourth quarter is in line with or slightly below its quarter-to-date results, this would result in comparable store sales growth for fiscal year 2008 of approximately 5%. Total sales growth, on a 52-week to 52-week basis, would be approximately 12% for the fourth quarter and approximately 23% for the fiscal year. The Company notes that sales in the fourth quarter last year included five weeks of the continuing Wild Oats stores, all subsequently closed Wild Oats stores, and the divested Henry's and Sun Harvest stores.
The Wild Oats stores will only be included in the comparable store base for the last four weeks of the fourth quarter and consequently are not expected to have a material impact on the Company's overall comparable store sales growth for the quarter.
In addition to the two stores that have opened so far in the fourth quarter, five to six additional stores are expected to open in the quarter, two of which are relocations.
The Company now expects a year-over-year decline in store contribution as a percentage of sales in the fourth quarter similar in magnitude to the 174 basis point decline in the third quarter.
The Company has already implemented certain cost containment measures and expects G&A in the fourth quarter to be in line with the $61 million reported in the third quarter.
The Company expects non-cash share-based payments expense of approximately $3 million to $4 million in the fourth quarter. The Company expects total pre-opening and relocation costs in the range of $20 million to $22 million for the fourth quarter, bringing the full year to $70 million to $72 million, at the low end of the Company's prior guidance of $70 million to $80 million. The Company expects interest expense, net of investment and other income, in the range of $8 million to $9 million in the fourth quarter, resulting in a range of $31 million to $32 million for the full year, below the Company's prior guidance of $35 million to $40 million due primarily to lower average interest rates throughout the year.
Based on these assumptions, the Company expects diluted earnings per share in the range of $0.13 to $0.15 for the fourth quarter, bringing the full year to $0.93 to $0.95 per share. The Company expects EBITDA of $98 million to $102 million for the fourth quarter, resulting in a range of $501 million to $505 million for the fiscal year. The Company expects EBITANCE of $113 million to $117 million in the fourth quarter, resulting in a range of $559 million to $563 million for the fiscal year.
The Company expects capital expenditures in the range of $160 million to $165 million in the fourth quarter, resulting in a range of $552 million to $557 million for the full fiscal year. This is below the Company's prior fiscal-year guidance of $575 million to $625 million due primarily to certain measures implemented in the third quarter to reduce discretionary capital expenditures not related to new stores.
Goals for Fiscal Year 2009 While the uncertain economic outlook makes it difficult to predict future sales results, the Company is providing the following preliminary assumptions and expectations for fiscal year 2009. The Company expects to update this guidance in its fourth quarter earnings announcement in early November.
Assuming no dramatic change in economic trends, the Company expects total sales growth in fiscal year 2009 of 6% to 10%. The Company expects comparable store sales growth of 1% to 5%, identical store sales growth of 0% to 4%, and approximately 15 new store openings, approximately six of which are relocations.
The Company has committed to significant cost reductions and expects G&A expenses of approximately 3.2% of sales in fiscal year 2009. The Company expects total pre-opening and relocation costs in the range of $50 million to $60 million versus the $70 million to $72 million expected in fiscal year 2008. Approximately half of this amount relates to pre-opening rent (primarily non-cash) for stores scheduled to open in fiscal year 2010 and beyond.
Assuming no significant change in interest rates, the Company expects interest expense, net of investment and other income, in the range of $35 million to $40 million in fiscal year 2009 versus the $31 million to $32 million expected in fiscal year 2008.
Based on these assumptions, the Company expects diluted earnings per share in the range of $1.08 to $1.14 in fiscal year 2009, including approximately $0.07 to $0.09 per share in dilution from Wild Oats and approximately $0.06 per share in dilution from the Company's U.K. operations. The Company expects EBITDA in the range of $560 million to $580 million and EBITANCE in the range of $625 million to $650 million in fiscal year 2009.
The Company is committed to managing its capital expenditures and does not intend to access the capital markets for additional funding in the foreseeable future. Capital expenditures in fiscal year 2009 are expected to be in the range of $400 million to $450 million compared to the $552 million to $557 million in capital expenditures expected in fiscal year 2008. About Whole Foods Market
Founded in 1980 in Austin, Texas, Whole Foods Market ( http://www.wholefoodsmarket.com) is the world's leading natural and organic foods supermarket and America's first national certified organic grocer. In fiscal year 2007, the Company had sales of $6.6 billion and currently has 272 stores in the United States, Canada, and the United Kingdom. Whole Foods Market employs more than 50,000 Team Members and has been ranked for eleven consecutive years as one of the "100 Best Companies to Work For" in America by FORTUNE magazine.
Forward-looking statements
The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, which could cause our actual results to differ materially from those described in the forward-looking statements. These risks include but are not limited to general business conditions, the successful integration of acquired businesses into our operations, changes in overall economic conditions that impact consumer spending, the impact of competition, changes in the Company's access to available capital, the successful resolution of ongoing FTC matters, and other risks detailed from time to time in the SEC reports of Whole Foods Market, including Whole Foods Market's report on Form 10-K for the fiscal year ended September 30, 2007. Whole Foods Market undertakes no obligation to update forward-looking statements.
The Company will host a conference call today to discuss this earnings announcement at 4:00 p.m. CT. The dial-in number is 1-800-862-9098, and the conference ID is "Whole Foods." A simultaneous audio webcast will be available at http://www.wholefoodsmarket.com. |